drugset / Trial / NCT06223074

Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration

NCT06223074

RandomizedParallel-groupDouble-blindTreatment

Summary

This Clinical Trial evaluates the nasal administration of Methylprednisolone as a treatment strategy for Acute Relapses in Multiple Sclerosis

Timeline

Start
2023-01-09
Primary completion
2026-02-25
Completion
2026-07-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylprednisolone Other / unclassified 1 g Intranasal